Company: BLRX
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001178913-25-003403
Chunk: 2

Company: BioLineRx Ltd.
Filing Date: 2025-09-29
Form: 6-K
Chunk 2
---
 events, including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of the JV to operate due to insufficient financial resources. The foregoing descriptions of the ATA and the JV Agreement are not complete and are qualified in their entirety by reference to the full text of such documents, copies of which are filed as exhibits to this Report on Form 6-K and are incorporated by reference herein. On September 29, 2025, the Company issued a press release entitled “BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Tumors.” A copy of the press release is attached hereto as Exhibit 99.1. This Report on Form 6-K, including all exhibits hereto (other than the press release attached as Exhibit 99.1), is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Attached hereto and incorporated by reference herein are the following exhibits:

| Exhibit No. |     | Description                                                                                                |
| 10.1(1)(2)  |     | Asset Transfer Agreement, dated as of September 29, 2025, between Hemispherian AS and Tetragon Biosciences 
 Ltd.                                                                                                       |
| 10.2(1)(2)  |     | Collaboration and Shareholders Agreement, dated as of September 29, 2025, between BioLineRx Ltd., Tetragon 
 Biosciences Ltd. and Hemispherian AS                                                                       |
| 99.1        |     | Press Release dated September 29, 2025                                                                     |

(1) Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish a copy of all omitted schedules and exhibits to the SEC upon its request. (2) Portions of this exhibit (indicated by asterisks) have been omitted under rules of the SEC permitting the confidential treatment of select information. The Registrant agrees to furnish a copy of all omitted information to the SEC upon its request. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| BioLineRx Ltd. |                         |
| By:            | /s/ Philip A. Serlin